University of Copenhagen

Antag Therapeutics secures €80 million Series A led by Versant Ventures for AT-7687, a novel obesity therapy. AT-7687, a weekly GIPR antagonist, aims to enhance weight loss when combined with GLP-1 therapies. The funding will accelerate clinical trials and pipeline expansion.

Antag Therapeutics raises 80 million euros to advance its GIP-inhibiting weight loss drug AT-7687 into clinical testing, exploring its combination with Novo Nordisk's Wegovy. The Series A round, led by Versant Ventures, includes Novo Holdings, SR One, Pictet, KKR-related entities, Broadview Ventures, and the Danish Export and Investment Fund. Antag's approach contrasts with Eli Lilly's GIP-activating Zepbound, with both methods debated. Combining GIP with GLP-1 appears more effective than GLP-1 alone, as seen in Lilly's SURMOUNT-5 trial. Antag's AT-7607, a GIP-blocking peptide, aims for fewer side effects and potential synergies with current and future therapies.

New RESOLUTION trial results show Vyepti® (eptinezumab) significantly reduces monthly migraine days (MMDs) in patients with chronic migraine and medication-overuse headache, with rapid benefits observed.

Outlook Therapeutics' ONS-5010 fails to meet noninferiority endpoint in phase III trial for wet AMD, but shows biologic activity and safety. Ocaliva's conditional marketing approval revoked in Europe. Arovella Therapeutics advances CAR-19-iNKT cell therapy ALA-101. UK bioethics council calls for new regulations on stem cell-derived embryo models. Copenhagen researchers identify NK2R signaling pathway affecting energy balance. Immune system's role in neurodegenerative diseases highlighted. Scholar Rock's apitegromab nears BLA submission. BioWorld investigates women's health disparities. BioWorld offices closed for Thanksgiving.

ICG-19 opens at BGI Group HQ in Shenzhen, gathering 100+ genomics leaders to discuss latest advancements in life sciences, emphasizing genomics' role in addressing global challenges like aging and public health.

A daily dose of vitamin B3 reduced lung inflammation in COPD patients by 53% after six weeks, increasing to 63% after 12 weeks, according to a Danish study. Researchers also observed increased NAD levels and slowed cellular aging, suggesting potential new treatment options for COPD.

Researchers discovered human antibodies targeting PfEMP1 proteins in severe malaria, potentially leading to vaccines or treatments. These antibodies, found effective against various PfEMP1 types, prevent parasite binding by recognizing conserved amino acids on CIDRα1, offering insights for PfEMP1-based interventions.

GLORIOUS study finds no improvement in clinical outcomes from using GLP-1 receptor agonist or restrictive oxygenation during CPB-assisted coronary artery surgery and/or valve replacement surgery.

The 32nd Semmelweis Symposium, focusing on network medicine, featured 35 global speakers discussing network science, drug repurposing, and AI in healthcare. Keynotes highlighted the potential of network medicine to revolutionize disease prevention, diagnosis, and treatment.

New weight loss drug suppresses appetite and burns calories without common side effects like nausea, potentially offering effective treatment for obesity and type 2 diabetes.